As reported by Healio, the U.S. Food and Drug Administration (FDA) has officially qualified AIM-MASH AI Assist, marking a milestone as the first artificial intelligence tool cleared to support drug development for metabolic dysfunction-associated steatohepatitis (MASH).
Developed by PathAI, AIM-MASH AI Assist leverages cloud-based machine learning to help pathologists evaluate liver biopsy samples in clinical trials. The system analyzes key histologic features — including steatosis, hepatocellular ballooning, lobular inflammation, and fibrosis stage — and generates standardized scores aligned with the MASH Clinical Research Network (CRN) criteria.
While the AI provides automated scoring, pathologists retain full responsibility for reviewing slides and validating results. This hybrid approach aims to reduce variability and improve efficiency compared to traditional manual scoring, which often requires multiple experts and can be time-intensive.
The model was trained on more than 100,000 annotations from 59 pathologists and nearly 6,000 biopsy samples across six clinical trials. According to PathAI’s Chief Medical Officer, Eric Walk, MD, the technology represents a “game-changing” advancement, addressing the limitations of human interpretation and accelerating the identification of effective therapies.
MASH, a severe form of fatty liver disease, poses a growing global health challenge, with many patients at risk for liver failure or cancer. By minimizing variability in trial data, AIM-MASH AI Assist is expected to streamline drug development and bring new treatments to patients faster.
